dc.creatorZlocowski, Natacha
dc.creatorGrupe, Verónica Maria
dc.creatorGaray, Yohana Camila
dc.creatorNores, Gustavo Alejandro
dc.creatorLardone, Ricardo Dante
dc.creatorIrazoqui, Fernando Jose
dc.date.accessioned2021-03-24T15:04:14Z
dc.date.accessioned2022-10-14T22:08:47Z
dc.date.available2021-03-24T15:04:14Z
dc.date.available2022-10-14T22:08:47Z
dc.date.created2021-03-24T15:04:14Z
dc.date.issued2019-12
dc.identifierZlocowski, Natacha; Grupe, Verónica Maria; Garay, Yohana Camila; Nores, Gustavo Alejandro; Lardone, Ricardo Dante; et al.; Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues; Nature Publishing Group; Scientific Reports; 9; 1; 12-2019; 1-11
dc.identifierhttp://hdl.handle.net/11336/128870
dc.identifier2045-2322
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4312227
dc.description.abstractDescribed in several epithelial cancer cells, Tn- (GalNAcα1-O-Ser/Thr) and T- (Galβ3GalNAcα1-O-Ser/Thr) antigens are examples of tumor-associated antigens. Increased expression of Tn- and T-antigens is associated with tumor invasion and metastasis, and patients with high concentration of anti-Tn and anti-T antibodies have a more benign evolution of pathology. Asialofetuin (ASF) and ovine submaxillary mucin (OSM) are two glycoproteins that expose T- and Tn-antigen, respectively. In this work, using ASF or OSM we affinity-purified anti-T and anti-Tn antibodies from normal human plasma and tested their ability to specifically recognize tumor human tissues. Whereas purified anti-T antibodies (purity degree increase of 127-fold, and 22% recovery) were mainly IgG, for purified anti-Tn antibodies (purity degree enhancement of 125-fold, and 26% yield) the IgM fraction was predominant over the IgG one. IgG2 subclass was significantly enriched in both purified antibody samples. Purified antibodies did not bind normal human tissue (0/42), although recognized malignant tissues from different origin such as colon carcinoma (11/77 by anti-Tn; 7/79 by anti-T), breast carcinoma (10/23 by anti-Tn; 7/23 by anti-T), and kidney carcinoma (45/51 by anti-Tn; 42/51 by anti-T). Our results suggest that purified human anti-Tn and anti-T antibodies have a potential as anti-tumor therapeutic agents; restoring their levels in human sera could positively affect the evolution of patients with epithelial tumor pathologies.
dc.languageeng
dc.publisherNature Publishing Group
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://www.nature.com/articles/s41598-019-44601-9
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1038/s41598-019-44601-9
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPurification process
dc.subjectHuman antibodies
dc.subjectCarcinoma recognition
dc.subjectProtein therapy
dc.titlePurified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución